Absci(ABSI) - 2025 Q4 - Annual Results

Exhibit 99.1 Absci Reports Business Updates and Fourth Quarter and Full Year 2025 Financial and Operating Results Successfully dosed first three cohorts in SAD portion of ongoing ABS-201™ HEADLINE trial; well-tolerated with favorable emerging safety data Unveiled human ex vivo data demonstrating that ABS-201 stimulates hair growth and regenerates follicle stem cell niche Appointed seasoned biopharmaceutical executive Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer Cash, cash equivalents, and marke ...